Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | MEN1 | O00255 | 1/20 | 0.54 |
| ▸ | ABL1 | P00519 | 1/20 | 0.51 |
| ▸ | RIN1 | Q13671 | 1/20 | 0.51 |
| ▸ | MAPT | P10636 | 2/20 | 0.48 |
| ▸ | LMNA | P02545 | 3/20 | 0.48 |
| ▸ | NPC1 | O15118 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 4/20 | 0.48 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.46 |
| ▸ | POLB | P06746 | 1/20 | 0.46 |
| ▸ | HCAR3 | P49019 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.44 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.44 |
| ▸ | NT5E | P21589 | 1/20 | 0.44 |
| ▸ | P2RY6 | Q15077 | 1/20 | 0.44 |
| ▸ | P2RY14 | Q15391 | 1/20 | 0.44 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22672647 | 0.86 | MEN1 (0.54) | KMT2AMEN1ABL1RIN1MAPT | |
| SCHEMBL7635962 | 0.86 | DEGS1 (0.48) | MAPTLMNANPC1RAB9ASMN1; SMN2 | |
| SCHEMBL7528362 | 0.85 | ADORA3 (0.51) | KMT2AMEN1MAPTNPC1RAB9A | |
| SCHEMBL454099 | 0.84 | MAPT (0.50) | KMT2AMEN1ABL1RIN1MAPT | |
| SCHEMBL8645717 | 0.83 | RAB9A (0.51) | KMT2AMEN1ABL1RIN1MAPT | |
| SCHEMBL8299962 | 0.83 | MEN1 (0.45) | KMT2AMEN1ABL1RIN1MAPT | |
| SCHEMBL27057456 | 0.83 | KMT2A (0.50) | KMT2AMEN1ABL1RIN1MAPT | |
| SCHEMBL26231024 | 0.82 | ABL1 (0.53) | KMT2AMEN1ABL1RIN1MAPT | |
| SCHEMBL27727547 | 0.81 | ABL1 (0.49) | KMT2AMEN1ABL1RIN1MAPT | |
| SCHEMBL9195212 | 0.80 | KMT2A (0.47) | KMT2AMEN1ABL1RIN1MAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180100036-A1 | CLICK NUCLEIC ACID POLYMERS AND METHODS OF USE | UNIV COLORADO REGENTS (US) | 2018-04-12 | — | — | US | disclosed |
| US-20180100036-A1 | CLICK NUCLEIC ACID POLYMERS AND METHODS OF USE | UNIV COLORADO REGENTS (US) | 2018-04-12 | — | — | US | disclosed |
| US-8859490-B2 | Peptide nucleic acid monomers and oligomers | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2014-10-14 | — | — | US | disclosed |
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2012-03-15 | — | — | US | disclosed |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHONOLOGICAL UNIVERSITY (SG) | 2011-10-06 | — | — | US | disclosed |
| US-7825215-B1 | Substituted nucleic acid mimics | Nielsen, Peter E. (DK) | 2010-11-02 | — | — | US | disclosed |
| WO-2010027326-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | NANYANG TECHNOLOGICAL UNIVERSITY (SG) | 2010-03-11 | — | — | WO | disclosed |
| US-6465650-B1 | INTERMEDIATE STEPS IN PREPARING PEPTIDE NUCLEIC ACIDS | AVENTIS PHARMA DEUTSCHLAND GMBH (DE) | 2002-10-15 | — | — | US | disclosed |
| EP-0646596-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1999-05-26 | — | — | EP | disclosed |
| US-5886177-A | ETHYLENE GLYCOL MONOMERS JOINED VIA STANDARD PHOSPHATE LINKAGES INCLUDING PHOSPHOROTHIOATE, PHOSPHODIESTER, AND PHOSPHORAMIDATE LINKAGES; USEFUL FUNCTIONAL GROUPS INCLUDE NUCLEOBASES AS WELL AS POLAR GROUPS, HYDROPHOBIC GROUPS | ISIS PHARMACEUTICALS, INC. (US) | 1999-03-23 | — | — | US | disclosed |
| EP-0646595-B1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1998-11-04 | — | — | EP | disclosed |
| EP-0863150-A1 | A method for the preparation of nucleic acid binding compound | BOEHRINGER MANNHEIM GMBH (DE) | 1998-09-09 | — | — | EP | disclosed |
| EP-0646595-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
| EP-0646596-A1 | Nucleic acid binding oligomers having C-branches for therapy and diagnosis | BAYER AG (DE) | 1995-04-05 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120065364-A2 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | KMT2A 3492/4885MEN1 4345/4885ABL1 4255/4885 |
| US-20110245458-A1 | PEPTIDE NUCLEIC ACID MONOMERS AND OLIGOMERS | SIN3A, POLR2H, CYTH3 | KMT2A 3492/4885MEN1 4345/4885ABL1 4255/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.